Tony Coles, Cerevel CEO
February 22, 2023 11:16 AM ESTUpdated February 24, 10:21 AM
People
R&D

Cerev­el blames Covid for de­layed neu­ro­science stud­ies, says pres­i­dent is leav­ing

Kyle LaHucik

Senior Reporter

Neu­ro­science biotech Cerev­el Ther­a­peu­tics said da­ta read­outs for sev­er­al clin­i­cal tri­als will come lat­er than orig­i­nal­ly ex­pect­ed, and al­so dis­closed the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times